• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corporation - Common Stock (NQ:INCY)

    122.77 -0.51 (-0.41%)
    Streaming Delayed Price Updated: 1:41 PM EDT, Sep 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 483,893
    Open 124.35
    Bid (Size) 122.73 (400)
    Ask (Size) 122.81 (400)
    Prev. Close 123.28
    Today's Range 121.61 - 124.35
    52wk Range 81.09 - 132.60
    Shares Outstanding 222,430,635
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today ↗
    Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of... 
    Via Benzinga
    News headline image
    2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
    A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
    Via StockStory

    Performance

    YTD
    +21.1%
    +21.1%
    1 Month
    +1.4%
    +1.4%
    3 Month
    +13.9%
    +13.9%
    6 Month
    +33.4%
    +33.4%
    1 Year
    +42.3%
    +42.3%

    More News

    Read More
    News headline image
    3 Market-Beating Stocks with Competitive Advantages
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup ↗
    Via Chartmill
    News headline image
    2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off
    Via StockStory
    Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience ↗
    Via Chartmill
    Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup ↗
    Via Chartmill
    Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut ↗
    Via Chartmill
    News headline image
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    News headline image
    Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years ↗
    Via Benzinga
    News headline image
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte Corporation
    Via Business Wire
    News headline image
    1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
    Via StockStory
    Topics Supply Chain
    INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings ↗
    Via Chartmill
    INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup ↗
    Via Chartmill
    Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation ↗
    Via Chartmill
    News headline image
    Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
    From Incyte
    Via Business Wire
    Exploring the top movers within the S&P500 index during today's session. ↗
    Via Chartmill
    Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. ↗
    Via Chartmill
    News headline image
    Incyte Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly
    Via StockStory
    News headline image
    Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
    From Incyte
    Via Business Wire
    News headline image
    What To Expect From Incyte’s (INCY) Q2 Earnings
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
    From Incyte
    Via Business Wire
    News headline image
    Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?
    Via StockStory
    Topics Stocks
    News headline image
    Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
    From Incyte
    Via Business Wire

    Frequently Asked Questions

    Is Incyte Corporation - Common Stock publicly traded?
    Yes, Incyte Corporation - Common Stock is publicly traded.
    What exchange does Incyte Corporation - Common Stock trade on?
    Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Incyte Corporation - Common Stock?
    The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
    What is the current price of Incyte Corporation - Common Stock?
    The current price of Incyte Corporation - Common Stock is 122.77
    When was Incyte Corporation - Common Stock last traded?
    The last trade of Incyte Corporation - Common Stock was at 09/11/26 01:41 PM ET
    What is the market capitalization of Incyte Corporation - Common Stock?
    The market capitalization of Incyte Corporation - Common Stock is 27.31B
    How many shares of Incyte Corporation - Common Stock are outstanding?
    Incyte Corporation - Common Stock has 27B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.